Netherlands Pharmaceuticals & Healthcare Report Q1 2015
Headline Expenditure Projections
- Pharmaceuticals: EUR6.09bn (USD8.04bn) in 2013 to EUR5.92bn (USD7.93bn) in 2014; -2.8% in local currency terms and -1.3% in US dollar terms.
- Healthcare: EUR70.37bn (USD92.89bn) in 2013 to EUR71.34bn (USD95.59bn) in 2014; 1.4% in local currency terms and 2.9% in US dollar terms.
The Netherlands continues to rank in the lower half of BMI's Pharmaceutical Risk/Reward Indices (RRIs) for the 15 key Western European markets, remaining 12th for Q115. The country fell from eighth in Q413. At 65.1, its overall RRI score remains slightly below the regional average of 68. This was the result of the rise of Finland and the incorporation of Denmark in our ratings system, both of which overtook the Netherlands. While the country offers drugmakers a relatively low-risk operating environment, poor market prospects - due to pressures on pricing and reimbursement and the market's maturity - will continue to weigh down its overall standing.
Key Trends And Developments
- to-BBB has reported significant additions to complete its new management team in addition to changing its name from to-BBB technologies to BBB Therapeutics. Dr Ferdinand Massari and Dr Pericles Calias have joined BBB as Chief Medical Officer and Chief Scientific Officer. Completing the management team are recently appointed CEO Dr Anders Harfstrand, CFO Leon Kruimer and Chief Business Officer Dr Carlos de...
The Netherlands Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Netherlands Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Dutch pharmaceutical and healthcare industry.
- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Netherlands to test other views - a key input for successful budgeting and strategic business planning in the Dutch pharmaceutical and healthcare market.
- Target business opportunities and risks in the Dutch pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Netherlands.
- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
BMI Industry View & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)
Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)
OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
Despite the Dutch economy expanding during the second quarter of 2014 at a time were the broader Eurozone have slowed, we believe the Netherlands ' patented and generic drugmakers face difficult challenges over the coming years. The government will likely remain committed to reduce drug prices as it tries to cope with the healthcare demands of a growing aging population. This coupled with a patent cliff along with health insurers looking to include cheaper generic medicines into their policies, keeps our outlook for the market subdued.
BMI Industry View
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Netherlands 2010-2018)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)
OTC Medicine Market Forecast
Table: OTC Medicine Sales Indicators By Category, 2008-2010
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecast (Netherlands 2012-2018)
Table: Pharmaceutical Trade Data And Forecasts local currency (Netherlands 2012-2018)
Other Healthcare Data
Table: Number Of Physicians By Type, 2007-2010
Key Risks To BMI's Forecast Scenario
Table: Netherlands - Economic Activity
Industry Risk Reward Ratings
Western Europe Risk/Reward Ratings
Netherlands Risk/Reward Ratings
Industry Trends And Developments
Table: Key Points Of The Dutch Health Insurance Act, January 1 2006
Healthcare Insurance Developments
Table: Biosimilars Approved In The EU
Research And Development
Intellectual Property Regime
Table: Pharmaceutical Production, 1995-2010 (EUR '000s)
Recent Company Activity
Pharmaceutical Wholesale Sector
Pharmaceutical Retail Sector
Merck & Co
Table: The Netherlands' Population By Age Group, 1990-2020 ('000)
Table: The Netherlands' Population By Age Group, 1990-2020 (% of total)
Table: The Netherlands' Key Population Ratios, 1990-2020
Table: The Netherlands' Rural And Urban Population, 1990-2020
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Ratings Methodology
Table: Pharmaceutical Risk/Reward Ratings Indicators
This report does not have a list of Companies Mentioned available
This report does not have a press release associated with it